Novartis’ psoriasis trial data for Cosentyx outshines Johnson and Johnson competitor
Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara.
According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90% reduction in the Psoriasis Area and Severity Index) compared to 47.9% of those treated with Stelara.
It was also found that at Week 12, patients who were receiving Cosentyx had significantly greater PASI 100 responses (completely clear skin) compared to those taking Stelara (38.1% versus 20.1% respectively).
At Week four, PASI 75 response rates were significantly superior with Cosentyx compared to Stelara (40.2% vs. 16.3%), while at Week 16, Novartis’ drug also demonstrated significantly superior response rates compared to Stelara for PASI 75 (91.7%vs. 79.8%), PASI 90 (76.6% vs. 54.2%) and PASI 100 (45.3% vs. 26.7%).
“These data add to the robust body of evidence supporting the use of Cosentyx to treat moderate to severe plaque psoriasis,” said Mark Lebwohl, MD and Chairman of the Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai Hospital in New York City.
“With these findings, clinicians can have even greater confidence including Cosentyx in their treatment plans.”
Cosentyx is the first and only fully human IL-17A inhibitor approved to treat psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).